CLINICAL_TRIALS
trial_result
· 2007-08-10
Clinical Trial Update: Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) [Phase 3]
Summary
A Phase 3 trial compared standard-dose Imatinib (400 mg daily) with high-dose Imatinib (800 mg daily) in chronic myeloid leukemia and has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Bologna | Conditions: Chronic Myeloid Leukemia | Phase 3 | Status: COMPLETED